← All trials
NCT03180307
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2018
- Primary completion
- Apr 16, 2020
- Completion date
- Oct 16, 2020
- First posted
- Jun 8, 2017
- Last posted
- Feb 4, 2022
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- On Target Laboratories, LLCLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- Synteract, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.